Gene Im, MD Email Gene Im
- ASSOCIATE PROFESSOR | Medicine, Liver Diseases
- Liver Medicine
- Liver Transplantation
- Hospital Affiliation
- The Mount Sinai Hospital
Dr. Gene Y Im is an Assistant Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. He earned his B.A. from the University of California, Berkeley, graduating with honors. He completed his Internal Medicine residency and fellowship in Gastroenterology at Winthrop-University Hospital, the primary teaching affiliate for the SUNY Stony Brook School of Medicine. He then completed an advanced fellowship in Transplant Hepatology at the Mount Sinai Medical Center. He is currently the Associate Program Director of the Transplant Hepatology fellowship and RSS course director of the Division of Liver Diseases at Mount Sinai.
Dr. Im’s areas of clinical interest include cirrhosis, acute/chronic liver diseases, portal hypertension, liver biopsy, quality improvement, endoscopy, inpatient care of liver patients and liver transplantation.
His research program focuses on alcoholic hepatitis and liver disease, including early liver transplantation for alcoholic hepatitis, portal hypertension, liver biopsy and outcomes-based research.
Dr. Im is an UNOS-certified Liver Transplant physician and is board certified in Internal Medicine, Gastroenterology and Transplant Hepatology. He is also a member of the American Association for the Study of Liver Diseases.
- Colon Polypectomy
- Endoscopic Band Ligation
- Esophageal Varices
- Flexible Sigmoidoscopy
- Hepatitis B
- Hepatitis C
- Liver Biopsy
- Liver Transplant
- Toxic Hepatitis
- Upper GI Endoscopy
Hepatitis C Virus, Liver, Transplantation
MD, New York Medical College
Residency, Internal Medicine
Winthrop University Hospital
Winthrop University Hospital
Fellowship, Transplant Hepatology
Mount Sinai School of Medicine
Outcomes of Inpatient Hospital Transfers to a Liver Transplant Center
The purpose of this study is to examine the characteristics and outcomes of patients referred for inpatient hospital transfer to Mount Sinai Medical Center. These patients anecdotally have poor clinical outcomes, but a systematic evaluation of this special population has not been performed. Multivariate analysis demonstrated that patients with acute on chronic liver failure were more likely to have inpatient mortality. Future efforts will focus on a cost analysis of inpatient hospital transfers to the liver service.
Emerging Therapies for Severe Alcoholic Hepatitis
Early liver transplantation for severe alcoholic hepatitis has recently been demonstrated to be a feasible and effective therapy for highly selected patients who fail medical therapy and violate the so-called “6 month rule,” using a rigorous evaluation program. Here at Mount Sinai, we are leading the North American experience of early liver transplantation as a rescue therapy for selected patients with severe alcoholic hepatitis. Particular areas of interest include patient selection, outcomes, burden on organ supply and alcohol relapse. Translational collaborations are being planned with the Alcoholic Liver Disease Research Center at Mount Sinai to further elucidate the pathogenesis of alcoholic hepatitis. Future clinical trials to evaluate therapies with less side-effects, more targeted therapies or those aimed hepatic regeneration are needed.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Im did not report having any of the following types of financial relationships with industry during 2019 and/or 2020: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.